Why AcelRx Pharmaceuticals (ACRX) Stock Is Plummeting Today

NEW YORK (TheStreet) -- AcelRx Pharmaceuticals  (ACRX) plummeted Monday after the FDA rejected the company's painkiller dispensing device Zalviso.

AcelRx announced the news late Friday that the FDA did not grant approval to the device. The FDA has some concerns about Zalviso and has asked for more data to "support the shelf life of the product," according to the agency's Complete Response Letter.

For more on this story, read TheStreet's Adam Feuerstein's article here.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

The stock was down 34.81% to $7.06 at 10:07 a.m.

ACRX Chart ACRX data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

Here's Why AcelRx Pharmaceuticals (ACRX) Stock Gained Today

AcelRx Pharmaceuticals (ACRX) Highlighted As Weak On High Volume

AcelRx Pharmaceuticals (ACRX) Strong On High Relative Volume Today

Amicus, Other Biotech CEOs Should Listen More, Talk Less About FDA Matters

5 Stocks Poised for Breakouts